Scholar Rock Q2 net loss narrows

Scholar Rock Holding

06/08/2026 12:22

Overview
US biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recorded
Operating expenses for Q2 fell, driven by reduced research and development costs
Company ended Q2 with $492 mln in cash, boosted by ATM program proceeds

Outlook
Scholar Rock expects potential FDA approval of apitegromab by September 30, 2026
Company prepared for immediate U.S. launch of apitegromab upon FDA approval
Scholar Rock engaging with EMA on next steps for apitegromab approval in Europe

Result Drivers
PIPELINE PROGRESS - Co cited advancement of apitegromab regulatory review and clinical trials as key business activities in Q2
COMMERCIAL PREPARATION - Co said it is prepared for U.S. apitegromab launch upon FDA approval, with commercial team active in the field

Company press release: ID:nBw3lrC4Pa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$109.90 mln
 
Q2 Income from Operations
 
-$108.90 mln
 
Q2 Operating Expenses
 
$108.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Scholar Rock Holding Corporation is $58.00, about 21.2% above its August 5 closing price of $47.87

Reuters Recommended Reads
Aug 5 - Biopharma firm MannKind Q2 posts net loss on product launch expenses
Aug 5 - Compass Pathways' Q2 loss widens on commercial readiness activity costs
Aug 5 - Black Diamond Therapeutics Q2 net loss narrows year over year

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)